bioAffinity Technologies, Inc. (BIAF)

Recent Quarterly Results

Source: Company filings

Price Chart

bioAffinity Technologies, Inc. (BIAF) stock price: $1.32 (+0.06, +4.76%)

Why Bull

• •Insiders buying recently? That often signals they see value the market is missing.
• •I'm seeing a lot of positive buzz in the community lately. Feels like the tide is turning on this one.
• •The overall market narrative seems to be shifting in favor of companies like this. Could be riding a wave.
• •There's a growing sense that this company is undervalued compared to its peers. Might be a catch-up play.

Why Bear

• •Insider activity can be misleading. Sometimes it's just window dressing, not a real conviction.
• •Community sentiment can be fickle. Remember the GameStop frenzy? Hype doesn't always equal profits.
• •Market narratives change fast. What's hot today is cold tomorrow. Be careful chasing trends.
• •Undervalued can mean a value trap. Maybe the market sees something we don't. Do your homework.

• 12 Health Care Stocks Moving In Wednesday's Intraday Session
  benzinga · Feb 4, 2026
• 12 Health Care Stocks Moving In Monday's After-Market Session
  benzinga · Feb 2, 2026
• Energy Fuels, Firefly Aerospace And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
  benzinga · Sep 30, 2025
• Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
  benzinga · Sep 29, 2025

Rationale

AI-generated technical analysis for BIAF including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for bioAffinity Technologies, Inc. (BIAF), choose a timeframe, and track your prediction accuracy.

Current price: $1.32

No insider trades in the last 30 days.

Score Factors

• Revenue Growth 10/100

  Revenue surged 194942.1% year-over-year, indicating explosive demand and rapid market share expansion.

• Gross Margin 6/100

  Gross margin of 27.9% is acceptable but leaves limited room for R&D and marketing investment.

• Operating Leverage 6/100

  Revenue growth is driving operating leverage, meaning profits can grow faster than costs.

• Cash Runway 5/100

  Cash position data is currently unavailable for this company.

• R&D Intensity 5/100

  R&D spending data is currently unavailable for this company.

• Insider Activity 6/100

  No significant insider buying or selling recently, which is neutral for the stock outlook.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates BIAF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Is BIAF a good stock to buy?

Whether BIAF is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the BIAF MoonshotScore?

The MoonshotScore for BIAF is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is BIAF data updated?

BIAF stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to BIAF is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for BIAF?

Growth catalysts for bioAffinity Technologies, Inc. (BIAF) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes bioAffinity Technologies, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are BIAF's main competitors?

bioAffinity Technologies, Inc. (BIAF) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether BIAF has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about BIAF?

Wall Street analyst coverage for BIAF includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is BIAF's market cap?

Market capitalization (market cap) for BIAF is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows BIAF's current market cap alongside enterprise value and other valuation metrics.

How has BIAF stock performed recently?

BIAF's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing BIAF's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in BIAF?

Key risk categories for BIAF include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures BIAF's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling BIAF?

Insider trading activity for BIAF tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is BIAF a good stock for beginners?

bioAffinity Technologies, Inc. (BIAF) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is BIAF for first-time investors?

Every stock carries risk, including bioAffinity Technologies, Inc. (BIAF). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like BIAF.

BIAF vs S&P 500: which is better for new investors?

The S&P 500 (SPY) offers broad diversification across 500 large U.S. companies, making it a lower-risk starting point for new investors. bioAffinity Technologies, Inc. (BIAF) is a single stock with higher potential upside but also more concentrated risk. Most financial advisors suggest new investors start with index funds like the S&P 500 and gradually add individual stocks like BIAF as they gain experience. Compare BIAF's MoonshotScore and volatility to the broad market before deciding.

What should beginners know before buying BIAF?

Before buying bioAffinity Technologies, Inc. (BIAF), beginners should understand: (1) the company's business model and how it makes money (see the Company Overview on this page), (2) its financial health through revenue growth and gross margins (see MoonshotScore Breakdown), (3) what analysts are saying (check the Analyst Consensus tab), and (4) the key risks (see Risk Factors). Start with a small position you are comfortable losing entirely, and consider dollar-cost averaging instead of investing a lump sum.

How much money do I need to start investing in BIAF?

You can start investing in bioAffinity Technologies, Inc. (BIAF) with as little as $1 through fractional shares, which most modern brokers offer. There is no minimum investment required. However, financial experts typically recommend only investing money you will not need for at least 3-5 years. Before buying BIAF, make sure you have an emergency fund covering 3-6 months of expenses and no high-interest debt. Check the current BIAF share price at the top of this page.